NovaBay auditor Withum declines 2025 reappointment

Rhea-AI Filing Summary

NovaBay Pharmaceuticals, Inc. reports that its longtime auditor, WithumSmith+Brown, PC, has declined to stand for re‑appointment as independent registered public accounting firm for the fiscal year ending December 31, 2025. Withum has audited NovaBay since 2010.

The audit reports for 2023 and 2024 contained no adverse or disclaimed opinions and no qualifications, other than an explanatory paragraph noting that NovaBay was seeking stockholder approval to dissolve and distribute all remaining assets to stockholders. The company states there were no disagreements or reportable events with Withum under SEC rules and has authorized Withum to fully cooperate with the successor firm.

NovaBay has requested, and filed as an exhibit, a letter from Withum to the SEC confirming its position and is in the process of identifying and engaging a new independent registered public accounting firm.

Insights

Equity & Governance Analyst

Longtime auditor exits amid orderly dissolution process and no reported disputes.

NovaBay discloses that WithumSmith+Brown, its auditor since 2010, will not stand for re‑appointment for the 2025 fiscal year. The company highlights that recent audit opinions for 2023 and 2024 were clean, aside from an explanatory paragraph about plans to seek stockholder approval to dissolve and distribute remaining assets.

The filing states there were no disagreements or reportable events under Item 304 of Regulation S‑K, and NovaBay has authorized full cooperation with a successor auditor. This positions the change as procedural within a wind‑down context rather than triggered by accounting disputes, though investors may still view any auditor transition during dissolution planning as an additional execution detail to track.

8-K Event Classification

2 items: 4.01, 9.01

2 items

Item 4.01 Changes in Registrant's Certifying Accountant Governance

The company changed its independent auditing firm, which may involve disagreements on accounting matters.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What auditor change did NovaBay Pharmaceuticals (NBY) disclose?

NovaBay disclosed that WithumSmith+Brown, PC declined to stand for re‑appointment as its independent registered public accounting firm for the fiscal year ending December 31, 2025. Withum had served as NovaBay’s auditor since 2010, making this a notable transition for the company.

Did NovaBay Pharmaceuticals (NBY) report any disagreements with WithumSmith+Brown?

NovaBay reported no disagreements with WithumSmith+Brown under Item 304(a)(1)(iv) of Regulation S‑K about accounting principles, financial statement disclosure, or audit procedures. The company also stated there were no reportable events under Item 304(a)(1)(v) during the referenced fiscal years and interim period.

What did WithumSmith+Brown’s recent audit reports for NovaBay (NBY) state?

Withum’s audit reports on NovaBay’s consolidated financial statements for 2023 and 2024 contained no adverse opinions, disclaimers, or qualifications related to uncertainty, scope, or principles. They did, however, include an explanatory paragraph noting NovaBay was seeking stockholder approval to dissolve and distribute remaining assets.

How is NovaBay Pharmaceuticals (NBY) handling the auditor transition?

NovaBay is in the process of identifying and engaging a new independent registered public accounting firm and plans to disclose the engagement once finalized. The company has authorized Withum to respond fully to the new auditor’s inquiries on all matters to support a smooth transition.

What document did WithumSmith+Brown provide to support NovaBay’s 8-K disclosure?

Withum furnished a letter to the Securities and Exchange Commission dated January 27, 2026, addressing whether it agrees with NovaBay’s statements about the auditor change. This letter is filed as Exhibit 16.1, providing formal confirmation of Withum’s position on the disclosed information.

How does NovaBay’s dissolution plan appear in the auditor’s report?

Withum’s audit report included an explanatory paragraph stating that NovaBay was seeking stockholder approval to dissolve the company and distribute all remaining assets to stockholders. This language highlights the company’s wind‑down intentions without modifying the overall audit opinion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/28/2026 - 04:10 PM Learn about SEC filing dates

false 0001389545 0001389545 2026-01-22 2026-01-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 22, 2026

NovaBay Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-33678		68-0454536
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2000 Powell Street, Suite 1150, Emeryville, CA 94608

(Address of principal executive offices and zip code)

(510) 899-8800

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		NBY		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.01. Changes in Registrant’s Certifying Accountant.

(a) Independent Registered Public Accounting Firm Declining to Stand for Re-appointment

On January 22, 2026, WithumSmith+Brown, PC (“Withum”) notified NovaBay Pharmaceuticals, Inc. (the “Company”) that they were declining to stand for re-appointment as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

Withum had served as the Company’s independent registered public accounting firm since 2010. Withum’s audit report on the Company’s consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain any adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles, except for an explanatory paragraph in its report regarding that the Company was seeking approval from its stockholders to dissolve and distribute all remaining assets to stockholders.

During the two most recent fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through the date of this Current Report on Form 8-K: there were (i) no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K between the Company and Withum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Withum’s satisfaction, would have caused Withum to make reference to the subject matter of the disagreements in connection with its report on the Company’s consolidated financial statements for such years, and (ii) no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K, and the Company has authorized Withum to respond fully to the inquiries of the successor independent registered public accounting firm on all matters.

In accordance with Item 304(a)(3) of Regulation S-K, the Company provided Withum with a copy of the disclosures it is making in this Current Report on Form 8-K and requested that Withum furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether Withum agrees with the statements made by the Company herein and, if not, stating the respects in which it does not agree. A copy of Withum’s letter dated January 27, 2026, is attached as Exhibit 16.1 to this Current Report on Form 8-K.

The Company is in the process of identifying and engaging a new independent registered public accounting firm and will disclose the engagement of a new auditor once finalized.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
16.1		Letter from WithumSmith+Brown, PC to the Securities and Exchange Commission dated January 27, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 28, 2026	NovaBay Pharmaceuticals, Inc.
	By:	/s/ Tommy Law
		Name:	Tommy Law
		Title:	Chief Financial Officer

-3-